Search results
Geron shares surge after U.S. FDA approves blood disorder drug
AOL· 24 minutes agoThe drug, which will be sold under the brand Rytelo, will compete with Bristol Myers Squibb's Reblozyl to treat transfusion-dependent anemia in patients with myelodysplastic syndromes - a group ...
Why Is Bristol Myers Squibb Stock Trading Higher On Friday? - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 7 days agoOn Thursday, the FDA approved Bristol Myers Squibb Co’s BMY Breyanzi (lisocabtagene maraleucel;...
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Zacks via Yahoo Finance· 2 days agoBristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy...
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
Insider Monkey via Yahoo Finance· 2 days agoWe recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co...
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe US Food and Drug Administration (FDA) awarded orphan drug designation to givastomig to treat...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 19 hours agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...
Anti-CD20 HGG Linked to Serious Infection Risk in MS
Medscape· 5 hours agoHypogammaglobulinemia is a known risk linked to B-cell–depleting therapies, but a real-world study has specified the risk and risk factors in multiple...
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC
MedPage Today· 5 days agoEGFR testing now needed for all patients with stage III disease, experts say
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 3 days agoTeva has a decent pipeline of biosimilars, with some being developed in partnership with Alvotech...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 6 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.